Skip to main content
S 2609 117th Congress Senate Health Health care costs and insurance Medical tests and diagnostic methods Medicare Radiation

Facilitating Innovative Nuclear Diagnostics Act of 2021

Introduced: August 4, 2021 Introduced by: Blackburn, Marsha Republican · Tennessee See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 4, 2021
Read twice and referred to the Committee on Finance.
Aug 4, 2021
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Facilitating Innovative Nuclear Diagnostics Act of 2021

This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2022 and as adjusted based on a specified fee schedule factor in each year thereafter.

What's happening now August 4, 2021

Read twice and referred to the Committee on Finance.

 Related & companion bills 1
  • HR 4479 Identical bill Facilitating Innovative Nuclear Diagnostics Act of 2021
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 7

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • FARRAGUT PARTNERS LLP
    for LANTHEUS MEDICAL IMAGING, INC. · Massachusetts · 2nd Quarter (Apr 1 - June 30) 2026
  • FARRAGUT PARTNERS LLP
    for LANTHEUS MEDICAL IMAGING, INC. · Massachusetts · 1st Quarter (Jan 1 - Mar 31) 2026
  • FARRAGUT PARTNERS LLP
    for LANTHEUS MEDICAL IMAGING, INC. · Massachusetts · 4th Quarter (Oct 1 - Dec 31) 2025
  • FARRAGUT PARTNERS LLP
    for LANTHEUS MEDICAL IMAGING, INC. · Massachusetts · 3rd Quarter (July 1 - Sep 30) 2025
  • FARRAGUT PARTNERS LLP
    for LANTHEUS MEDICAL IMAGING, INC. · Massachusetts · 2nd Quarter (Apr 1 - June 30) 2025
  • FARRAGUT PARTNERS LLP
    for LANTHEUS MEDICAL IMAGING, INC. · Massachusetts · 2nd Quarter (Apr 1 - June 30) 2025
See all 7 filings →
 Cosponsors 5
All 5 Democratic 3 Republican 2
D
Hassan, Margaret Wood
New Hampshire · Sep 21, 2022
 R
Capito, Shelley Moore
West Virginia · Apr 27, 2022
 D
Duckworth, Tammy
Illinois · Feb 3, 2022
 R
Sullivan, Dan
Alaska · Dec 7, 2021
 D
Baldwin, Tammy
Wisconsin · Aug 4, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). S. 2609: Facilitating Innovative Nuclear Diagnostics Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-S-2609/
MLA
"S. 2609: Facilitating Innovative Nuclear Diagnostics Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-2609/.
Bluebook (legal)
S. 2609, 117th Cong. (2026), https://openamerica.io/bill/117-S-2609/.
Markdown link
[S. 2609: Facilitating Innovative Nuclear Diagnostics Act of 2021](https://openamerica.io/bill/117-S-2609/)
Report a problem